Analytical Data
-
Gene name
dLL3
- Application
-
Alternative Names
dLL3；Delta-like Protein 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NYJ7
-
Expression Region
27-492aa
-
AA Sequence
AGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESP CALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIET WREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRA RCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSP EHGFCEQPGECRCLEGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPG PCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGPCFNGGL CVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALR CRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDC RERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASAL PAAPPGLRPGDPQRYL
-
Molecular Weight
51 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DLL3 (Delta-like 3) is a member of the Notch ligand family and plays a crucial role in the regulation of cell differentiation, proliferation, and development, particularly in the nervous system. Its expression is notably upregulated in various tumor types, especially neuroendocrine tumors, making it a potential target for therapeutic strategies. Research has increasingly focused on the use of DLL3 as a biomarker for tumor diagnosis and treatment, especially in small cell lung cancer (SCLC). The development of DLL3-targeted therapies, such as antibody-drug conjugates, aims to exploit its overexpression in tumors to deliver cytotoxic agents selectively to cancer cells. Recombinant DLL3 protein has been produced for various studies to understand its structure-function relationships, signaling pathways, and interaction with the Notch signaling pathway. The exploration of DLL3's role in tumor biology and its potential as a therapeutic target is a significant area of interest, as it could lead to innovative treatment options for patients with DLL3-positive tumors. Current research continues to assess the efficacy and safety of DLL3-targeted therapies in clinical trials, hoping to provide new avenues for cancer treatment and improve patient outcomes.
